Thermedical Awarded $3 Million NIH Grant to Study Promising Treatment for Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death
Retrieved on:
Tuesday, October 10, 2023
Medical Devices, Health, Hospitals, Surgery, Clinical Trials, Cardiology, Arrhythmia, National Heart, Lung, and Blood Institute, FHRS, Vanderbilt University Medical Center, Safety, Lung, Facial muscles, FDA, SERF, Clinical trial, Durable medical equipment, Bangladesh Technical Education Board, Shock, Ventricular tachycardia, Patient, Quality of life, NIH, ICD, Pharmaceutical industry, Medical device
VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.
Key Points:
- VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.
- Sudden cardiac death kills 325,000 adults in the U.S. every year1.
- "SERF ablation is a new approach that has the potential to improve treatment of this arrhythmia.
- Today, VT patients with ICDs who experience VT episodes may be treated with conventional RF ablation, a lengthy procedure with a moderate success rate of approximately 50%.